Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

被引：166

作者：

Collins, Peter W. ^{[1
]}

Chalmers, Elizabeth ^{[2
]}

Hart, Daniel P. ^{[3
]}

Liesner, Ri ^{[4
]}

Rangarajan, Savita ^{[5
]}

Talks, Kate ^{[6
]}

Williams, Mike ^{[7
]}

Hay, Charles R. ^{[8
]}

机构：

[1] Cardiff Univ, Univ Wales Hosp, Sch Med, Cardiff CF10 3AX, S Glam, Wales

[2] Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland

[3] Queen Mary Univ, Royal London Hosp, London Sch Med & Dent, London, England

[4] Great Ormond St NHS Trust, London, England

[5] Hampshire Hosp NHS Fdn Trust, Basingstoke & N Hampshire Hosp, Basingstoke, Hants, England

[6] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England

[7] Birmingham Childrens Hosp NHS Fdn Trust, Birmingham, W Midlands, England

[8] Cent Manchester Univ Hosp, Manchester, Lancs, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 160卷 / 02期

关键词：

haemophilia; inhibitor; immune tolerance induction; haemostasis; factor VIII; IX; bypassing agents; RECOMBINANT FACTOR-VIII; PREVIOUSLY UNTREATED PATIENTS; IMMUNE TOLERANCE INDUCTION; ACTIVATED FACTOR-VII; B-DOMAIN DELETION; F8 GENE MUTATION; A PATIENTS; PROPHYLACTIC TREATMENT; ORTHOPEDIC-SURGERY; RISK-FACTORS;

D O I：

10.1111/bjh.12091

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：153 / 170

页数：18

共 131 条

[31] Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study [J].

Dargaud, Yesim ;

Luddington, Rodger ;

Gray, Elaine ;

Negrier, Claude ;

Lecompte, Thomas ;

Petros, Sirak ;

Hogwood, John ;

Bordet, Jean-Claude ;

Hogwood, John ;

Bordet, Jean-Claude ;

Regnault, Veronique ;

Siegemund, Annelie ;

Baglin, Trevor .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (02) :303-309

[32] Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery [J].

Dargaud, Yesim ;

Lienhart, Anne ;

Negrier, Claude .

BLOOD, 2010, 116 (25) :5734-5737

[33] A retrospective postlicensure survey of FEIBA efficacy and safety [J].

DiMichele, D. ;

Negrier, C. .

HAEMOPHILIA, 2006, 12 (04) :352-362

[34] Immune tolerance therapy dose as an outcome predictor [J].

Dimichele, D .

HAEMOPHILIA, 2003, 9 (04) :382-386

[35] The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy [J].

Dimichele, D. .

HAEMOPHILIA, 2009, 15 (01) :320-328

[36]

DiMichele DM, 2002, THROMB HAEMOSTASIS, V87, P52

[37] Inhibitor development in haemophilia B: an orphan disease in need of attention [J].

DiMichele, Donna .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (03) :305-315

[38]

Eckhardt C, 2012, HAEMOPHILIA, V18, P96

[39] Surgery and inhibitor development in hemophilia A: a systematic review [J].

Eckhardt, C. L. ;

van der Bom, J. G. ;

Van der Naald, M. ;

Peters, M. ;

Kamphuisen, P. W. ;

Fijnvandraat, K. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (10) :1948-1958

[40] Intensive peri-operative use of factor VIII and the Arg593→Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A [J].

Eckhardt, C. L. ;

Menke, L. A. ;

van Ommen, C. H. ;

van der Lee, J. H. ;

Geskus, R. B. ;

Kamphuisen, P. W. ;

Peters, M. ;

Fijnvandraat, K. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (06) :930-937

← 1 2 3 4 5 6 7 8 9 10 →